Compare XMAX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMAX | GYRE |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.8M | 606.4M |
| IPO Year | 2009 | 2004 |
| Metric | XMAX | GYRE |
|---|---|---|
| Price | $8.98 | $6.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 574.0K | 47.4K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.51 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $12,744,871.00 | $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.10 | $5.44 |
| 52 Week High | $9.40 | $9.42 |
| Indicator | XMAX | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 53.40 |
| Support Level | $8.33 | $5.67 |
| Resistance Level | $9.34 | $8.28 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 51.41 | 49.58 |
XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.